Home / Latest Reports / Duchenne Muscular Dystrophy Dmd Drugs Market

Duchenne Muscular Dystrophy (DMD) Drugs Market - Global Industry Analysis And Forecast To 2027

Published On : December 2018 Pages : 170 Category: Petrochemicals Report Code : CM122157

Request Sample Inquiry Before Buying Request for Customization Check Discount

Duchenne Muscular Dystrophy (DMD) Drugs Market By Therapeutic Approach (Steroid Therapy, Exon Skipping and Mutation Suppression); - Global Industry Analysis And Forecast To 2027         

Industry Outlook

Duchenne Muscular Dystrophy (DMD), is a genetic disorder affecting the muscles, here muscles deteriorate and weaken. Muscular dystrophy is divided into 9 different types. Duchenne Muscular Dystrophy (DMD) is caused due to deficiency of dystrophin, protein responsible for keeping the muscle cells bonded. Mainly boys are affected by this disease, girls related cases are less. Duchenne Muscular Dystrophy (DMD) Drugs use is growing due to factors like; rise in the research & development, new techniques involved for treatment, increasing urge for powerful treatment methods to deal with the disorder, rising number of cases, etc. Therefore, the Duchenne Muscular Dystrophy (DMD) Drugs Market is anticipated to expand and has tremendous scope during the forecast period. The global Duchenne Muscular Dystrophy (DMD) Drugs Market anticipated to flourish in the future by growing at a significantly higher CAGR.

Market Segmentation

The global Duchenne Muscular Dystrophy (DMD) Drugs Market is based on segment, by Therapeutic Approach the market is segmented into Steroid Therapy, Exon Skipping and Mutation Suppression.

  • Duchenne Muscular Dystrophy (DMD) Drugs Market, By Therapeutic Approach
  • Steroid Therapy
  • Exon Skipping
  • Mutation Suppression

Regional Insights

On a global front, the Duchenne Muscular Dystrophy (DMD) Drugs Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). North American region is leading the Duchenne Muscular Dystrophy (DMD) Drugs Market, due to technical development, high budgetary spending on Healthcare and initiatives by government by undertaking awareness programs.

Duchenne Muscular Dystrophy (DMD) Drugs Market, By Region

    • North America
  • U.S.
  • Canada
  • Mexico
    • Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
    • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Rest of Asia-Pacific
    • South America
  • Brazil
  • Argentina
  • Columbia
  • Rest of South America
    • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of MEA

Competitive Analysis

The leading players in the market are Catabasis, Santhera, Sarepta, Italfarmaco and PTC. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.

  • Catabasis
  • Santhera
  • Sarepta
  • Italfarmaco
  • PTC

Some of the key questions answered by the report are:          

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

o   Duchenne Muscular Dystrophy (DMD) Drugs Market, By Therapeutic Approach, Estimates and Forecast, 2017-2027 ($Million)

o   Steroid Therapy

o   Exon Skipping

o   Mutation Suppression

Duchenne Muscular Dystrophy (DMD) Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o   North America

§  North America Duchenne Muscular Dystrophy (DMD) Drugs Market, By Country

o   U.S. Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Canada Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Mexico Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Europe

§  Europe Duchenne Muscular Dystrophy (DMD) Drugs Market, By Country

o   Germany Duchenne Muscular Dystrophy (DMD) Drugs Market

o   UK Duchenne Muscular Dystrophy (DMD) Drugs Market

o   France Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Russia Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Italy Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Rest of Europe Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Asia-Pacific

§  Asia-Pacific Duchenne Muscular Dystrophy (DMD) Drugs Market, By Country

o   China Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Japan Duchenne Muscular Dystrophy (DMD) Drugs Market

o   South Korea  Duchenne Muscular Dystrophy (DMD) Drugs Market

o   India Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Southeast Asia Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Rest of Asia-Pacific Duchenne Muscular Dystrophy (DMD) Drugs Market

o   South America

§  South America Duchenne Muscular Dystrophy (DMD) Drugs Market, By Country

o   Brazil Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Argentina Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Columbia Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Rest of South America Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Middle East and Africa

§  Middle East and Africa Duchenne Muscular Dystrophy (DMD) Drugs Market, By Country

o   Saudi Arabia Duchenne Muscular Dystrophy (DMD) Drugs Market

o   UAE Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Egypt Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Nigeria Duchenne Muscular Dystrophy (DMD) Drugs Market

o   South Africa Duchenne Muscular Dystrophy (DMD) Drugs Market

o   Rest of MEA Duchenne Muscular Dystrophy (DMD) Drugs Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Duchenne Muscular Dystrophy (DMD) Market, By Therapeutic Approach

5.1.     Introduction

5.2.     Global Duchenne Muscular Dystrophy (DMD) Revenue and Market Share by Therapeutic Approach  (2017-2027)

5.2.1.  Global Duchenne Muscular Dystrophy (DMD) Revenue and Revenue Share by Therapeutic Approach  (2017-2027)

5.3.     Steroid Therapy

5.3.1.  Global Steroid Therapy Revenue and Growth Rate (2017-2027)

5.4.     Exon Skipping

5.4.1.  Global Exon Skipping Revenue and Growth Rate (2017-2027)

5.5.     Mutation Suppression

5.5.1.  Global Mutation Suppression Revenue and Growth Rate (2017-2027)

6.       Duchenne Muscular Dystrophy (DMD) Market, By Region

6.1.     Introduction

6.2.     Global Duchenne Muscular Dystrophy (DMD) Revenue and Market Share by Regions

6.2.1.  Global Duchenne Muscular Dystrophy (DMD) Revenue by Regions (2017-2027)

6.3.     North America Duchenne Muscular Dystrophy (DMD) by Countries

6.3.1.  North America Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2027)

6.3.2.  North America Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2027)

6.3.3.  United States

6.3.3.1.  United States Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.4.  Canada

6.3.4.1.  Canada Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.5.  Mexico

6.3.5.1.  Mexico Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.     Europe Duchenne Muscular Dystrophy (DMD) by Countries

6.4.1.  Europe Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2027)

6.4.2.  Europe Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2027)

6.4.3.  Germany

6.4.3.1.  Germany Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.4.  France

6.4.4.1.  France Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.5.  UK

6.4.5.1.  UK Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.6.  Russia

6.4.6.1.  Russia Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.7.  Italy

6.4.7.1.  Italy Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.8.  Rest of Europe

6.4.8.1.  Rest of Europe Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.     Asia-Pacific Duchenne Muscular Dystrophy (DMD) by Countries

6.5.1.  Asia-Pacific Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2027)

6.5.2.  Asia-Pacific Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2027)

6.5.3.  China

6.5.3.1.  China Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.4.  Japan

6.5.4.1.  Japan Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.5.  Korea

6.5.5.1.  Korea Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.6.  India

6.5.6.1.  India Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.7.  Southeast Asia

6.5.7.1.  Southeast Asia Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.8.  Rest of Asia-Pacific

6.5.8.1.  Rest of Asia-Pacific Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.     South America Duchenne Muscular Dystrophy (DMD) by Countries

6.6.1.  South America Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2027)

6.6.2.  South America Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2027)

6.6.3.  Brazil

6.6.3.1.  Brazil Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.4.  Argentina

6.6.4.1.  Argentina Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.5.  Columbia

6.6.5.1.  Columbia Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.6.  Rest of South America

6.6.6.1.  Rest of South America Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.     Middle East and Africa Duchenne Muscular Dystrophy (DMD) by Countries

6.7.1.  Middle East and Africa Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2027)

6.7.2.  Middle East and Africa Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2027)

6.7.3.  Saudi Arabia

6.7.3.1.  Saudi Arabia Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.4.  United Arab Emirates

6.7.4.1.  United Arab Emirates Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.5.  Egypt

6.7.5.1.  Egypt Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.6.  Nigeria

6.7.6.1.  Nigeria Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.7.  South Africa

6.7.7.1.  South Africa Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.8.  Turkey

6.7.8.1.  Turkey Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.9.  Rest of Middle East and Africa

6.7.9.1.  Rest of Middle East and Africa Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

7.       Company Profiles

7.1.     Catabasis

7.1.1.  Business Overview

7.1.2.   Service Portfolio

7.1.3.  Strategic Developments

7.1.4.   Revenue and Market Share

7.2.     Santhera

7.2.1.  Business Overview

7.2.2.   Service Portfolio

7.2.3.  Strategic Developments

7.2.4.   Revenue and Market Share

7.3.     Sarepta

7.3.1.  Business Overview

7.3.2.   Service Portfolio

7.3.3.  Strategic Developments

7.3.4.   Revenue and Market Share

7.4.     Italfarmaco

7.4.1.  Business Overview

7.4.2.   Service Portfolio

7.4.3.  Strategic Developments

7.4.4.   Revenue and Market Share

7.5.     PTC

7.5.1.  Business Overview

7.5.2.   Service Portfolio

7.5.3.  Strategic Developments

7.5.4.   Revenue and Market Share

8.       Global Duchenne Muscular Dystrophy (DMD) Market Competition, by Manufacturer

8.1.     Global Duchenne Muscular Dystrophy (DMD) Revenue and Market Share by Manufacturer (2017-2017)

8.2.     Global Duchenne Muscular Dystrophy (DMD) Price By Region (2017-2017)

8.3.     Top 5 Duchenne Muscular Dystrophy (DMD) Manufacturer Market Share

8.4.     Market Competition Trend

9.       Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.1.     Global Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2027)

9.2.     Duchenne Muscular Dystrophy (DMD) Market Forecast by Regions (2017-2027)

9.2.1.  North America Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.1.1.  United States Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.1.2.  Canada Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.1.3.  Mexico Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.2.  Europe Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.2.1.  Germany Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.2.2.  France Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.2.3.  UK Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.2.4.  Russia Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.2.5.  Italy Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.2.6.  Rest of Europe Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.3.  Asia-Pacific Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.3.1.  China Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.3.2.  Japan Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.3.3.  Korea Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.3.4.  India Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.3.5.  Southeast Asia Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.3.6.  Rest of Asia-Pacific Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.4.  South America Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.4.1.  Brazil Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.4.2.  Argentina Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.4.3.  Columbia Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.4.4.  Rest of South America Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.5.  Middle East and Africa Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.5.1.  Saudi Arabia Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.5.2.  United Arab Emirates Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.5.3.  Egypt Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.5.4.  Nigeria Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.5.5.  South Africa Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.5.6.  Turkey Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.2.5.7.  Rest of Middle East and Africa Duchenne Muscular Dystrophy (DMD) Market Forecast (2017-2027)

9.3.     Duchenne Muscular Dystrophy (DMD) Market Forecast by Therapeutic Approach  (2017-2027)

9.3.1.  Duchenne Muscular Dystrophy (DMD) Forecast by Therapeutic Approach  (2017-2027)

9.3.2.  Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Therapeutic Approach  (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Duchenne Muscular Dystrophy (DMD) Revenue and Revenue Share by Therapeutic Approach (2017-2018)
Figure Global Steroid Therapy Revenue and Growth Rate (2017-2018)
Figure Global Exon Skipping Revenue and Growth Rate (2017-2018)
Figure Global Mutation Suppression Revenue and Growth Rate (2017-2018)
Table Global Duchenne Muscular Dystrophy (DMD) Revenue by Regions (2017-2018)
Figure North America Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure North America Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2018)
Figure North America Duchenne Muscular Dystrophy (DMD) by Countries (2017-2018)
Figure North America Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2018)
Figure United States Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure United States Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Canada Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Mexico Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Europe Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2018)
Figure Europe Duchenne Muscular Dystrophy (DMD) by Countries (2017-2018)
Figure Europe Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2018)
Figure Germany Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Germany Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure France Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure UK Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Russia Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Italy Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Rest of Europe Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy (DMD) by Countries (2017-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2018)
Figure China Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure China Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Japan Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Korea Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure India Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Southeast Asia Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure South America Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2018)
Figure South America Duchenne Muscular Dystrophy (DMD) by Countries (2017-2018)
Figure South America Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Brazil Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Argentina Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Columbia Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Rest of South America Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy (DMD) by Countries (2017-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Saudi Arabia Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure United Arab Emirates Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Egypt Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Nigeria Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure South Africa Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Turkey Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Duchenne Muscular Dystrophy (DMD) Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2017-2018)
Table Catabasis Duchenne Muscular Dystrophy (DMD) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Santhera Duchenne Muscular Dystrophy (DMD) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sarepta Duchenne Muscular Dystrophy (DMD) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Italfarmaco Duchenne Muscular Dystrophy (DMD) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table PTC Duchenne Muscular Dystrophy (DMD) Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Duchenne Muscular Dystrophy (DMD) Market Share by Manufacturer
Figure Global Duchenne Muscular Dystrophy (DMD) Revenue and Market Share by Manufacturer
Table Global Duchenne Muscular Dystrophy (DMD) Price by Region (2017-2017)
Figure Top 5 Duchenne Muscular Dystrophy (DMD) Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Duchenne Muscular Dystrophy (DMD) Revenue (Millions USD) and Growth Rate (2018-2025)
Table Duchenne Muscular Dystrophy (DMD) Market Forecast by Regions (2018-2025)
Figure North America Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure United States Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Canada Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Mexico Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Europe Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Germany Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure France Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure UK Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Russia Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Italy Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Rest of Europe Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Asia-Pacific Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure China Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Japan Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Korea Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure India Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Southeast Asia Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure South America Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Brazil Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Argentina Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Columbia Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Rest of South America Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Middle East and Africa Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Saudi Arabia Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure United Arab Emirates Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Egypt Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Nigeria Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure South Africa Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Turkey Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Duchenne Muscular Dystrophy (DMD) Market Forecast (2018-2025)
Figure Global Duchenne Muscular Dystrophy (DMD) Forecast by Therapeutic Approach (2018-2025)
Figure Global Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Therapeutic Approach (2018-2025)
Figure Global Duchenne Muscular Dystrophy (DMD) Forecast by Therapeutic Approach (2018-2025)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*